Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. Company
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Seagen Inc.
Seagen Inc. specializes in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows:

- sales from licensing and collaboration agreements (48.2%);

- sales of products (48%);

- royalties (5.8%).

Number of employees : 2 092 people.
Sales per Business
20192020Delta
Pharmaceutical Products916.71100%2 175.54100% +137.32%
USD in Million
Sales per region
20192020Delta
United States916.71100%2 175.54100% +137.32%
USD in Million
Managers
Name Title Age Since
Clay Siegall Director & Chief Scientific Officer 60 1997
Todd Simpson Chief Financial Officer 60 2005
Vaughn Himes Chief Technical Officer 60 2016
Roger Dansey Chief Medical Officer 64 2018
Marc E. Lippman, Dr. Independent Director 76 2000
Felix James Baker, Dr. Lead Independent Director 52 2003
David W. Gryska Independent Director 65 2005
Daniel Welch Independent Director 63 2007
Nancy A. Simonian, Dr. Independent Director 60 2012
John A. Orwin Independent Director 56 2014
Members of the board
Name Title Age Since
Clay Siegall Director & Chief Scientific Officer 60 1997
Marc E. Lippman, Dr. Independent Director 76 2000
Felix James Baker, Dr. Lead Independent Director 52 2003
David W. Gryska Independent Director 65 2005
Daniel Welch Independent Director 63 2007
Nancy A. Simonian, Dr. Independent Director 60 2012
John A. Orwin Independent Director 56 2014
Alpna H. Seth, Dr. Independent Director 58 2018
Ted W. Love, Dr. Director 61 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 182,855,795 181,662,051 99.3% 0 0.0% 99.3%
Shareholders
NameEquities%
Baker Bros. Advisors LP 47,063,823 25.7%
Capital Research & Management Co. (International Investors) 12,893,510 7.05%
Wellington Management Co. LLP 12,191,481 6.67%
The Vanguard Group, Inc. 11,765,553 6.43%
Capital Research & Management Co. (Global Investors) 7,799,217 4.27%
T. Rowe Price Associates, Inc. (Investment Management) 6,989,864 3.82%
PRIMECAP Management Co. 4,835,900 2.64%
JPMorgan Investment Management, Inc. 3,554,266 1.94%
Cascade Investment LLC 3,521,088 1.93%
SSgA Funds Management, Inc. 3,315,465 1.81%
Holdings
NameEquities%Valuation
PIERIS PHARMACEUTICALS, INC. (PIRS) 3,706,174 5.14% 14,009,338 USD
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 /
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  SGEN.O
- Datastream Code :  
Company contact information
Seagen Inc.
Building 3 21823 30th Drive S E
WA 98021 Bothell, Washington

Phone : +1 425 527 4000
Fax :
web site : https://investor.seagen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Seagen Inc.
Sector Other Biotechnology & Medical Research